Eurazeo Patrimoine announces the acquisition of C2S GROUP
Eurazeo Patrimoine, the Eurazeo division specializing in investments in tangible assets, is pleased to announce the acquisition of C2S Group from Bridgepoint. The investment company will invest c. €100 million to become the group’s majority shareholder, alongside management and medical practitioners.
The transaction is subject to the approval of the French Competition authority and should be completed in the first quarter of 2018. C2S Group is the eighth largest private clinic operator in France and a regional leader in Auvergne, Rhône-Alpes and Burgundy Franche-Comté. It operates 11 clinics, primarily specializing in short and medium-length stays in general medicine, surgery and follow-up care. It also wns the buildings for seven of its clinics. The group has 500 medical practitioners, who are partners in the group’s governance and nearly 1,800 employees. In 2016, it treated over 235,000 patients (75% as outpatients) and reported revenue of €158 million. The group’s growth is founded on long-term societal trends. The French hospital care market was €195 billion 2015 (second largest in Europe) and is growing steadily.
C2S also enjoys an ideal regional footprint in one of the most densely populated and attractive areas in France. C2S Group has strengthened the management of its operations and real estate assets, while implementing an active external growth strategy,acquiring notably Hôpital Privéd’Ambérieu in 2015 and the Avenir Santé Group in 2016.
Since 2015, it has invested heavily in modernizing the group and improving its operating performance, benefiting from a relationship of trust with regional health authorities. Eurazeo Patrimoine’s experience in accompanying companies, combined with its real estate management expertise and its historical knowledge of the region, will drive the acceleration of C2S Group’s development, particularly through external growth.
For Renaud Haberkorn, Managing Partner and Head of Eurazeo Patrimoine: “We’re thrilled to offer our real estate and operational support and expertise to C2S Group. Its development and transformation in recent years has been quite remarkable. With its strong local footprint and Eurazeo Patrimoine’s support, we’re sure the group will continue its growth momentum and seize the many development opportunities available to it. This investment fits perfectly with Eurazeo Patrimoine’s strategy at the crossroads of the real estate and private equity businesses.”
For Jean Rigondet, Chairman of C2SGroup: “We’re delighted to welcome Eurazeo onboard and to work together to continue the group’s development strategy. With Bridgepoint ’s support, we successfully completed several projects and undertook essential work across all our clinics. We’re now eager to start a new chapter in C2S Group’s history alongside Eurazeo Patrimoine.
Further improvements in performance will be founded on exemplary medical governance and our teams, of which we are immensely proud, confirming our position in the Greater Center-East region.”
About Eurazeo
With a diversified portfolio of approximately ~€8 billion in assets under management, Eurazeo is a leading global investment company with offices in Paris and Luxembourg, New York, Shanghai and Sao Paolo. Its purpose and mission is to identify, accelerate and enhance the transformation potential of the companies in which it invests. The firm covers most private equity segments through its five business divisions – Eurazeo Capital, Eurazeo Croissance, Eurazeo PME, Eurazeo Patrimoine and Eurazeo Brands. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. As a global long-term shareholder, the firm offers deep sector expertise, a gateway to global markets, and a stable foothold for transformational growth to the companies it supports.
Eurazeo is listed on Euronext Paris.
ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA
